The goal of this exploratory study is to evaluate the safety and efficacy of nimotuzumab combined with chemoradiotherapy in bladder - preserving treatment for MIBC patients who are ineligible for or decline radical cystectomy. The main questions it aims to answer are:
Does nimotuzumab combined with radiotherapy reduce adverse events in elderly bladder cancer patients? Does this combination improve objective response rate (ORR), progression - free survival (PFS), overall survival (OS), and bladder preservation rate in these patients? Participants will be MIBC patients treated with nimotuzumab and chemoradiotherapy, with a planned 5 - year follow - up to assess treatment efficacy and safety.

Start Date30 Jun 2025

Sponsor / Collaborator

Peking University First Hospital

NCT06912711

/ RecruitingPhase 2IIT

Toripalimab Combined With Nimotuzumab Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma：A Single-arm, Phase II Clinical Tria

Investigators target recurrent nasopharyngeal carcinoma that can be resected surgically: rT1, rT2 (tumor confined to the surface of the parapharyngeal space, greater than 0.5cm from the internal carotid artery), rT3 (confined to the floor of the sphenoid sinus, greater than 0.5cm from the internal carotid artery/cavernous sinus) (AJCC 8th stage), A single-arm, phase II clinical trial was designed to investigate the efficacy and safety of triplizumab combined with nituzumab in induction and adjuvant treatment of operable local recurrent nasopharyngeal carcinoma.

Start Date16 May 2025

Sponsor / Collaborator

Sun Yat-Sen University

ChiCTR2500101420

/ SuspendedPhase 2IIT

A single-arm, single-center, open, prospective phase II clinical study of camrelizumab combined with nimotuzumab and first-line chemoradiotherapy for the treatment of recurrent and metastatic cervical cancer

Start Date01 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Nimotuzumab

100 Translational Medicine associated with Nimotuzumab

100 Patents (Medical) associated with Nimotuzumab

460

Literatures (Medical) associated with Nimotuzumab

01 Jun 2025·BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Nimotuzumab and irinotecan synergistically induce ROS‐mediated apoptosis by endoplasmic reticulum stress and mitochondrial‐mediated pathway in cervical cancer

Article

Author: Teng, Fei ; Zhao, Lujun

Abstract:

Irinotecan (CPT‐11), a chemotherapeutic agent used to treat several types of cancer, induces cytotoxic effects on healthy cells. The epidermal growth factor receptor (EGFR) plays a crucial role in various forms of cancer. Nimotuzumab (NmAb), a monoclonal antibody that targets the EGFR, is utilized in some countries to treat malignancies that have an overexpression of EGFR. Yet, there is a lack of literature on the potential anticancer properties of the CPT‐11 and NmAb combination on in vitro human cervical cancer cells. This study investigates the apoptosis mode of the CPT‐11 and NmAb combination on cervical HeLa cancer cells. The Annexin V/propidium iodide staining examination demonstrated that the combination of CPT‐11 and NmAb resulted in a decrease in the number of viable cells and more potent induction of cell apoptosis than the effects of CPT‐11 or NmAb alone in HeLa cells. Furthermore, the combined treatment resulted in elevated levels of reactive oxygen species (ROS) and Ca2+ compared to the treatment with CPT‐11 or NmAb alone. Cells that were pretreated with N‐acetyl‐l‐cysteine, a substance that scavenges ROS, and then treated with CPT‐11, NmAb, or a combination of CPT‐11 and NmAb exhibited higher numbers of viable cells compared to those treated with CPT‐11 or NmAb alone. The combination of CPT‐11 and NmAb resulted in significantly higher caspase‐3, ‐8, and ‐9 activity levels than CPT‐11 or NmAb alone, as measured by flow cytometer assay. The combination of CPT‐11 and NmAb in HeLa cells resulted in elevated endoplasmic reticulum stress‐, mitochondria‐, and caspase‐mediated proteins compared to treatment with CPT‐11 or NmAb alone. According to these observations, NmAb enhances the effectiveness of CPT‐11 in fighting cancer by stimulating cell death in the HeLa cells. Therefore, NmAb has the potential to improve the efficacy of CPT‐11 as a future cervical cancer treatment in humans.

01 Jun 2025·INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nimotuzumab Combined With Chemoradiation Therapy in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

Article

Author: Sun, Xiaoyang ; Xu, Jiankun ; Qiu, Xiaoguang ; Wang, Heling ; Li, Huan ; Zhao, Yongrui ; Zhang, Jing ; Kou, Zhen ; Liu, Yanwei ; Chen, Baoshi ; Shen, Liangfang ; Tao, Rongjie ; Wang, Shujun ; Zhang, Hui ; Lin, Qingtang ; Yang, Jia ; Su, Jun ; Zhang, Wei ; Tang, Jianbing ; Wang, Longyun ; Liu, Chao ; Ma, Wenbin ; Hong, Jidong ; Sun, Peng ; Chen, Shuxian ; Shi, Xuejiao ; Zhu, Chuanying ; Zeng, Gao ; Wang, Yu ; Wang, Gang ; Liu, Shuai ; Jiang, Mawei ; Ju, Yan ; Bao, Wenlan

PURPOSE:

Diffuse intrinsic pontine glioma (DIPG) is a rare and fatal pediatric malignancy of the brainstem with a lack of effective therapeutic options. This study assesses the efficacy and safety of adding nimotuzumab to temozolomide (TMZ) chemoradiation therapy for newly diagnosed pediatric DIPG.

METHODS AND MATERIALS:

We conducted an open-label, single-arm, prospective, multicenter study involving children aged 3-15 years with histologically or radiographically confirmed DIPG from April 3, 2021 to April 13, 2023. Nimotuzumab (150 mg/m²/wk) was administered concurrently with local radiation therapy (54 Gy/30 f) and TMZ (75 mg/m²/d) for 6 weeks, followed by adjuvant TMZ (150-200 mg/m² for 5 consecutive days of a 28-day cycle for 6 cycles) and nimotuzumab (150 mg/m² biweekly until to disease progression). The primary endpoint was objective response rate (ORR). The secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. Adverse events were summarized using descriptive statistics.

RESULTS:

Of 48 enrolled patients, with a median age of 7 years (4-14), 28 (58.3%) were histologically confirmed, and 25 (89.3%) had H3K27M mutations. With a median follow-up of 26.5 months (95% CI, 14.6-not applicable), the ORR was 37.5%; the median OS and PFS were 10.5 (8.3-11.2) and 7.8 (5.1-8.4) months; and 1-year OS and PFS rates were 33.3% and 26.9%, respectively. Multivariate analysis showed that a partial response and no steroid use were associated with favorable OS. Distant metastasis was observed in 7 patients (14.6%). The most common grade ≥ 3 treatment-related adverse events were leukopenia (27.1%), lymphopenia (27.1%), and neutropenia (25.0%).

CONCLUSIONS:

Adding nimotuzumab to chemoradiation therapy is feasible, with ORR and survival rates favorably comparable with previous data in pediatric DIPG, despite not meeting the prespecified statistical significance for improved ORR compared with historical data. The overall safety profile was manageable, with no new safety concerns.

01 May 2025·CANCER CELL

Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma

Article

Author: Li, Yong Hong ; Cao, Zheng Guo ; Liu, Zhuo Wei ; Yan, Ru ; Zhou, Fang Jian ; Han, Hui ; Chen, Xiao Feng ; Luo, Guang Heng ; Luo, Jie Xin ; An, Xin ; Xue, Ting ; Ma, Hua Li ; Lei, Yong Hong ; Qi, Lin ; Chen, Mei Ting ; Zhang, Ying Chun ; Xue, Cong ; Shi, Yan Xia ; Xie, Qun ; Dong, Pei ; Liu, Zhi Zhong ; Hu, Zhi Quan ; Guo, Sheng Jie ; Yao, Kai ; Li, Ji Bin ; Liang, Pei Yu ; Xiong, Long Bin ; Zhang, Zhi Ling ; Sheng, Xi Nan ; Chen, Nan Hui ; Liu, Ting Yu ; Li, Xiang ; Li, Zai Shang ; Xu, Wen Feng ; Spiess, Philippe E ; Shi, Ben Kang

The conventional neoadjuvant chemotherapy regimen for locally advanced penile squamous cell carcinoma (La-PSCC) has shown moderate response rates and survival benefits. This single-arm, phase II trial (NCT04475016) evaluated a neoadjuvant regimen of four cycles of toripalimab (anti-PD-1 antibody), nimotuzumab (anti-EGFR antibody), and taxol-based chemotherapy (TNT), followed by consolidative surgery. The primary endpoint was the pathological complete response (pCR) rate. Among 29 enrolled patients, 24 (82.8%) underwent consolidative surgery, with 14 (48.3%, 95% confidence interval [CI], 29.4-67.5%) achieving pCR. The objective response rate (ORR) was 82.8% (95% CI, 64.2-94.2). Median follow-up was 39.97 months, with two-year overall survival (OS) and progression-free survival (PFS) rates of 72.4% and 65.5%. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 12 (41.4%) patients, with no treatment-related deaths. Biomarker analysis identified PD-L1 expression, TP53 mutation status, and CD8⁺ T cell density as potential predictive markers. Therefore, neoadjuvant TNT shows promising anti-tumor activity and acceptable toxicity.

News (Medical) associated with Nimotuzumab

14 Sep 2022

·www.globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents including temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 (ibudilast) as well as the other therapeutic agents. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc. commented, “We are very pleased to receive the issue notification for this new patent as it offers additional coverage compared to our other two patents covering glioblastoma. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at the Dana-Farber Cancer Institute, Harvard Medical School. Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone, and this data was presented at the American Society of Clinical Oncology (ASCO) annual meeting. Encouragingly, the FDA granted orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma based on this data.” About Glioblastoma According to the American Association of Neurological Surgeons, glioblastoma is an aggressive brain cancer that often results in death during the first 15 months after diagnosis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows rapidly, and commonly spreads into nearby brain tissue. Glioblastoma is classified as Grade IV, the highest grade, in the World Health Organization (WHO) brain tumor grading system. The American Brain Tumor Association reports that glioblastoma represents about 15% of all primary brain tumors and approximately 10,000 cases of glioblastoma are diagnosed each year in the U.S. Despite decades of advancements in neuroimaging, neurosurgery, chemotherapy and radiation therapy, only modest improvements have been achieved and the prognosis has not improved for individuals diagnosed with glioblastoma. Median survival is about 11-15 months for adults with more aggressive glioblastoma (IDH-wildtype) who receive standard treatment of surgery, temozolomide, and radiation therapy. About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova, Inc.info@medicinova.com

Radiation TherapySmall molecular drugASCOCollaborateIPO

25 Sep 2019

·www.biospace.com

Biocon Biologics Expands its R&D Footprint Through Acquisition

60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists 60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists Bengaluru, Karnataka, India: September 24, 2019: Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, today announced that its subsidiary, Biocon Biologics , has acquired R&D capital assets for a 60,000 sq. ft state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India Ltd. Dr Christiane Hamacher, CEO, Biocon Biologics, said: “The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide. This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale. R&D is at the core of what we do and I believe this facility will enable us to pursue breakthrough innovation in pursuit of providing affordable access to high quality biosimilars and inclusive healthcare solutions aimed at transforming patient lives globally.” The facility will house an early stage research and innovation center including a pilot scale R&D Unit, well-equipped with cell line development, drug substance process development from bench scale to 400 litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to state of the art R&D labs equipped with over 500 high- end process and analytical instrumentation. The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of our biosimilars portfolio. Currently, Biocon Biologics has a 200,000 sq. ft state of the art Research & Development Centre at Biocon Park, Bengaluru, India. The Company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. The financial details of the deal are confidential. TICEL Bio Park at Chennai, Tamil Nadu, India, is a hub for the biotech R&D industry in major domains such as medical biotechnology, nutraceuticals, agricultural biotechnology and bioinformatics and provides world class infrastructure support. About Biocon Biologics Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is uniquely positioned as the fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in the developed markets of EU, U.S. and Japan. It has obtained approvals and commercialized a range of biosimilars, including monoclonal antibodies for cancer, Pegfilgrastim, rh-Insulin and Insulin Glargine on its own or through partners in key global markets. Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives. About Biocon Ltd: Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. The Company has developed and commercialized a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh- Insulin and Insulin Glargine), Novel Biologics and differentiated Small Molecules in India and key emerging markets. It has a large portfolio of biosimilars and promising novel assets in immunotherapy under global development. Some of its key formulations brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). Follow-us on Twitter: @bioconlimited FOR MORE INFORMATION MEDIA RELATIONS Seema Ahuja Sr. VP & Global Head, Corporate Communications (+91 80 2808 2222 ( +91 99723 17792 * seema.ahuja@biocon.com INVESTOR RELATIONS Saurabh Paliwal Head, Investor Relations ( +91 80 6775 2040 ( +91 95383 80801 * investor.relations@biocon.com DISCLAIMER : This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

ImmunotherapyDrug ApprovalAcquisition

100 Deals associated with Nimotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nimotuzumab	L01XC	DB06192

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pancreatic Cancer	China	Biotech Pharmaceutical Co., Ltd.	07 Jun 2023
Squamous Cell Carcinoma of Head and Neck	Indonesia	Innogene Kalbiotech Pte Ltd.	19 Oct 2022
Nasopharyngeal Carcinoma	China	Biotech Pharmaceuticals Pty Ltd	07 Jan 2008
Glioma	Ukraine	Oncoscience AG	10 Oct 2007
Head and Neck Neoplasms	India	Biocon Biopharmaceuticals Pvt Ltd.	11 Sep 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrooesophageal junction cancer	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Metastatic Colorectal Carcinoma	Phase 3	-	Biotech Pharmaceutical Co., Ltd.	01 Apr 2024
Gastroesophageal junction adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	24 Jul 2023
stomach adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	24 Jul 2023
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2021
Diffuse Intrinsic Pontine Glioma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	03 Apr 2021
Cervical Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	10 May 2016
Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	13 Nov 2015
Metastatic Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2015
Uterine Cervical Cancer	Phase 3	Algeria	-	28 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04223024 (phase 2 trial, ASCO2025)	Phase 2	Advanced Nasopharyngeal Carcinoma plasma Epstein-Barr virus (EBV) DNA \| EGFR expression	-	CCRT plus Nimotuzumab	dvyglspumb(biboaowcvl) = oirfpiuxhj qcjbsjqzbe (wptqkycflu, 72.8 - 86.9)	Negative	30 May 2025
				CCRT alone	dvyglspumb(biboaowcvl) = dzkdxnebqw qcjbsjqzbe (wptqkycflu, 72.7 - 86.7)
NCT06781073 (ASCO2025)	Not Applicable	First line EGFR expression level	118	Nimotuzumab + Chemotherapy	ceabokbcqc(xqwcjpbcbf) = rngrpoobgy zyijexxfvz (dszayfpbhx, 11.8 - 26.9) View more	Positive	30 May 2025
				Chemotherapy Alone	ceabokbcqc(xqwcjpbcbf) = zxazheugxv zyijexxfvz (dszayfpbhx, 7.9 - 21.0) View more
ASCO2025	Not Applicable	Pancreatic Cancer Neoadjuvant EGFR	15	Nimotuzumab + Gemcitabine/nab-paclitaxel	kghznmvxlo(edlwdikxgl) = ghtxfoqozl yzekwnqzmh (uyozoaxtkg ) View more	Positive	30 May 2025
				Nimotuzumab + FOLFIRINOX	kghznmvxlo(edlwdikxgl) = adsfzblpqh yzekwnqzmh (uyozoaxtkg )
ASCO2025	Not Applicable	EGFR mutation	19	Nimotuzumab + Chemotherapy	eofocckmmc(xpombnqqvf) = carrxxvgxh fwuqpboqiq (qfgaiwmacm, 33.2 - 76.3) View more	Positive	30 May 2025
NCT06771596 (CC11, ASCO2025)	Phase 2	-	40	Nimotuzumab 400 mg	lbzsykhfhn(jtfsnbplsi) = atsrsjsxid ghzvlbexnk (rgvwiarhtz, 62.53 - 88.97) View more	Positive	30 May 2025
				Cisplatin 40mg/m2	lbzsykhfhn(jtfsnbplsi) = fwuirylltt ghzvlbexnk (rgvwiarhtz, 59.33 - 86.91)
ASCO2025	Phase 2	Advanced Esophageal Squamous Cell Carcinoma Second line PD-1/PD-L1	46	Camrelizumab plus Nimotuzumab	mkbdilfgku(hcfezfnjis) = gjglcwlqji qjfekqekdp (adoxacglgg, 19.5% - 48.0) View more	Positive	30 May 2025
ASCO2025	Not Applicable	Advanced Nasopharyngeal Carcinoma EBV DNA level	43	Serplulimab plus docetaxel and cisplatin	xlwlofxmcm(ihawsdrbpr) = patients with renal impairment experienced no additional adverse effects jikqamtxvx (smkklgefaw ) View more	-	30 May 2025
NCT03708822 (Pubmed \| BMC Med)	Phase 2	Nasopharyngeal Carcinoma First line plasma Epstein-Barr virus (EBV) DNA level	52	Nimotuzumab + Docetaxel + Cisplatin	efdstpzwbz(taobmtkmwn) = naqcbjfsaf skisizdddc (fitvdjfasq ) View more	Positive	06 May 2025
NCT06405685 (Phase II study of Nimotuzumab combined with AG regimen in pancreatic cancer with liver metastases (PCLM), AACR2025)	Phase 2	Pancreatic Cancer	26	Nimotuzumab + AG regimen	hutcudkqxu(eklvysgobm) = qqgxncstgs thuixqnzwj (yqwsbaqaud ) View more	Positive	29 Apr 2025
ASCO_GI2025	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma First line EGFR	58	Nimotuzumab + Chemotherapy + Immunotherapy	kqojvniqmz(bkwjfsqqwu) = mbeioofgil ljdqmumblt (dijvaglfov, 0.6 - 0.8) View more	Positive	23 Jan 2025
				Chemotherapy + Immunotherapy	hbileknesx(pwxueuxoix) = jpurxbsvqb ckqkrsikcq (xetnsdojmb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis